# Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center (DILIN) (U01 - Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-dk-22-508-limited-competition-for-the-continuation-of-the-drug/  
Official notice: https://www.grants.gov/search-results-detail/343236

> National Institutes of Health offered grants to colleges and universities. Applications closed on October 27, 2022.

| Field | Value |
|---|---|
| Opportunity number | RFA-DK-22-508 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | October 27, 2022 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.847 |

## Who can apply

- Public and State controlled institutions of higher education

Other Eligible Applicants include the following: Only the current recipient(s) under RFA-DK-17-510 are eligible to apply to this Funding Opportunity Announcement. Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

## What the grant funds

This Funding Opportunity Announcement is a limited competition for the continuation of the Data Coordinating Center of the Drug-induced Liver Injury Network (DILIN). The Data Coordinating Center will provide managerial, logistic, and analytic functions for the DILIN and build a collaboration with the National Center for Natural Products Research (NCNPR), University of Mississippi to attempt the identification of specific hepatotoxic ingredients in Herbal and Dietary Supplements (HDS) implicated in liver toxicity. This RFA and companion [RFA-DK-22-013, Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01 - Clinical Trial Optional)] will seek the continuation of the Data Coordinating Center and several Clinical Centers. Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 19 years, the DILIN through its publications has become the major source of information and progress in understanding and possibly decreasing the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide. The Network has made major advances in the understanding of the clinical presentation and outcomes of liver injury due to drugs as well as herbal and dietary supplements (HDS). These advances have led to exploratory inroads on the pathogenesis of DILI. DILIN remains the only structured, systematic and prospective effort in the United States and world-wide to characterize drug and HDS induced liver injury. The ultimate aims of DILIN are to elucidate the clinical and pathophysiologic features of DILI so as to allow inroads into its understanding, treatment and prevention, thus decreasing the burden of this disease.

## Questions people ask

### Is RFA-DK-22-508 still open?

No. It closed on October 27, 2022.

### Who can apply for Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center (DILIN) (U01 - Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from colleges and universities. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center (DILIN) (U01 - Clinical Trial Not Allowed)?

Closed October 27, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-DK-22-508?

NIH RePORTER lists 1 project funded under RFA-DK-22-508 in fiscal 2023 to 2026, at 1 institution.

### Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.